We provide answers, so you can focus on care
One test. Big picture. Brighter futures.
Our mission is to deliver personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery.
At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis.
Fueled by one of the world's largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers.
Our state-of-the-art interpretation platform, paired with our robust data set, make us the go-to lab when doctors need diagnoses for children with both rare diseases and common conditions.
Latest news
GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
April 4, 2024
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the first quarter of 2024 after the market closes on Monday, April 29, 2024.
GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
March 14, 2024
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced its scientific contributions at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
GeneDx to Participate in 44th Annual Cowen Health Care Conference
February 26, 2024
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.